From Diagnostic Imaging by Jeff Hall
A multivariable model that includes mpMRI and blood testing assessment of prostate extracellular vesicles had a significantly higher AUC and sensitivity rate than mpMRI alone for predicting clinically significant prostate cancer, according to research presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU).
Combining multiparametric magnetic resonance imaging (mpMRI) with prostate extracellular vesicle assessment and prostate-specific antigen (PSA) density may facilitate improved prediction of clinically significant prostate cancer (csPCa) and help reduce unnecessary prostate biopsies.
For the study, recently presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU) in San Francisco, researchers reviewed data from 175 patients (median age of 65) who had mpMRI, blood tests and a prostate biopsy. The treatment cohort had a mean prostate-specific antigen (PSA) level of 6.4 ng/mL, according to the study.
For the detection of csPCa, researchers compared imaging alone with mpMRI, a model that combined mpMRI and six-transmembrane epithelial antigen of the prostate extracellular vesicle (STEAP1-EV) density and a multivariable model that combined mpMRI, STEAP1-EV density, PSA density and prostate health index (PHI) density.
Researchers found that the multivariable model had a 90 percent area under the curve (AUC) for predicting csPCA in comparison to 77 percent for the mpMRI/STEAP1-EV density combination model and 66 percent for mpMRI alone.